Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.05.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Xiaozhen Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, CD47 Antigen, Tumor Microenvironment, Receptors, Tumor Necrosis Factor, Type II. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a major cause of cancer deaths, with poor outcomes in advanced stages. CD47, overexpressed in CRC, helps tumors evade immune detection by blocking macrophage phagocytosis, while CD47 blockade has shown limited efficacy in CRC. Our study showed that dual blockade of CD47 and TNFR2 demonstrated synergistic antitumor effects in murine CRC models. Since TNFR2 was highly expressed on Tregs and M-MDSCs, combination therapy targeting both CD47 and TNFR2 was tested, resulting in improved tumor control, prolonged survival, and enhanced immune responses by reducing Tregs and M-MDSCs, further increasing CD8+ T cell activation and macrophage function. A bispecific antibody fusion protein targeting both CD47 and TNFR2, called ATA47, demonstrated comparable efficacy to the combination therapy. Incorporating ATA47 into an oncolytic adenovirus (AdV-ATA47) also enhanced tumor control and immune activation with minimal systemic effects. AdV-ATA47 demonstrated significant antitumor effects in both murine and human tumor models, supporting its potential as a therapeutic strategy, particularly in combination with approved CRC therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
- State Key Laboratory of Pharmaceutical Biotechnology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China; Department of Pathogen Biology, School of Medicine, Nantong Universit…
- State Key Laboratory of Pharmaceutical Biotechnology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China. Electronic address: wjw@nju.edu.cn.
Förderung
- State Key Laboratory of Pharmaceutical Biotechnology
- Nanjing University
- National Natural Science Foundation of China
Zitieren
APA
Kang, X., Li, Y., Han, Y., Wu, M., Qian, P., Dong, J., & Wei, J. (2025). Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.05.032
Vancouver
Kang X, Li Y, Han Y, Wu M, Qian P, Dong J, et al. Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.05.032
BibTeX
@article{Kang2025,
author = {Kang, Xiaozhen and Li, Yuxin and Han, Yifeng and Wu, Mengdi and Qian, Peng and Dong, Jie and Wei, Jiwu},
title = {Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.05.032}
}
EUVIMED